Junliang Lu
Peking Union Medical College Hospital
31 Papers
91 Citations
Junliang Lu is an academic researcher from Peking Union Medical College Hospital. The author has contributed to research in topics: Medicine & KRAS. The author has an hindex of 14, co-authored 24 publications.
Chat about Author
Papers
Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
Jing Zhang,Jianming Zheng,Yinghong Yang,Junliang Lu,Jie Gao,Tao Lu,Jian Sun,Jiang Hui,Yan Zhu,Yuhui Zheng,Zhiyong Liang,Tong-hua Liu +11 more
TL;DR: Differences in the genetic profiles of KRAS, NRAS, PIK3CA and BRAF at mutation hotspots between Chinese CRC patients and those of Western countries were revealed, while some of these gene features were shared among patients from other Asian countries.
Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms.
TL;DR: This is the first study to show that Asporin promotes EMT, invasion, and migration of PCCs by activating CD44-AKT/ERK-NF-κB pathway in paracrine and autocrine manners.
85
BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
Jian Sun,Jing Zhang,Junliang Lu,Jie Gao,Xinyu Ren,Lianghong Teng,Huanli Duan,Yansong Lin,Xiaoyi Li,Bo Zhang,Zhiyong Liang +10 more
TL;DR: The prevalence and clinicopathological associations of BRAF V600E and TERT promoter mutations in Chinese PTC patients were determined and it was determined that the BRAFV600E mutation was associated with more advanced TNM stage upon diagnosis.
YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation.
Ying Xiao,Hui Zhang,Qiang Ma,Rui Huang,Junliang Lu,Xiaolong Liang,Xuguang Liu,Zhiwen Zhang,Lianyuan Yu,Junyi Pang,Liangrui Zhou,Tonghua Liu,Tonghua Liu,Huanwen Wu,Huanwen Wu,Zhiyong Liang,Zhiyong Liang +16 more
TL;DR: This study revealed a critical role for YAP1 in the regulation of PSC activation and paracrine signaling and provides insights into a novel rationale for targeting Yap1 to reprogram the PDAC microenvironment.
55
AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway.
TL;DR: The role of AREG in tumour growth in vivo was further determined using an orthotopic model of pancreatic cancer and it was found that AREG may play a critical role in cell migration, invasion, and EMT by activating the EGFR/ERK/NF-κB signalling pathway in pancreatic cancers cells.